TY - JOUR
T1 - Mental Health and Substance Use Among Adults with Disabilities During the COVID-19 Pandemic — United States, February-March 2021
AU - Czeisler, Mark E.
AU - Board, Amy
AU - Thierry, Jo Ann M.
AU - Czeisler, Charles A.
AU - Rajaratnam, Shantha M.W.
AU - Howard, Mark E.
AU - Clarke, Kristie E.N.
N1 - Funding Information:
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Charles A. Czeisler reports an institutional grant paid to Monash University from the CDC Foundation (funding provided by BNY Mellon); an institutional grant to Monash University from WHOOP, Inc.; being the incumbent of an endowed professorship provided to Harvard Medical School by Cephalon, Inc. in 2004; institutional support for Quality Improvement Initiative from Delta Airlines and Puget Sound Pilots; education/research support from Jazz Pharmaceuticals PLC, Inc., Philips Respironics, Inc., Regeneron Pharmaceuticals, and Sanofi S.A.; educational grant funding from ResMed, Teva Pharmaceuticals Industries Ltd., Australia and Vanda Pharmaceuticals, Inc.; royalty payments from Philips Respironics, Inc. on sales of the Actiwatch-2 and Actiwatch-Spectrum devices; personal consultancy and lecture fees from Physician’s Seal, LLC, State of Washington Board of Pilotage Commissioners, Vanda Pharmaceuticals, Inc., Teva Pharmaceutical Industries, Ltd, Australia, Tencent Holdings, Ltd, and the National Sleep Foundation (Chair, Sleep Timing and Variability Consensus Panel); payment for expert witness testimony related to matters involving Aegis Chemical Solutions, Amtrak, Casper Sleep, Inc., Enterprise Rent-A-Car, Dallas Police Association, FedEx, PAR Electrical Contractors, Inc., Puget Sound Pilots, Schlumberger Technology Corp., Union Pacific Railroad, United Parcel Service, and Vanda Pharmaceuticals, Inc.; travel support from Tencent Holdings, Ltd., Aspen Brain Institute, Bloomage International Investment Group, Inc., Stanley Ho Medical Development Foundation, German National Academy of Sciences, National Safety Council, and the National Sleep Foundation; membership AARP advisory board, Children and Screens: Institute of Digital Media and Child Development, Klarman Family Foundation, and Biotechnology and Biological Sciences Research Council (U.K.); equity interest in Vanda Pharmaceuticals, Inc.; and institutional educational gifts to Brigham and Women’s Hospital from Johnson & Johnson and Harmony Biosciences, LLC. Mark É. Czeisler reports institutional grants paid to Monash University from the CDC Foundation (funding provided by BNY Mellon), and from WHOOP, Inc.; funding from the Australian-American Fulbright Foundation (funding provided by the Kinghorn Foundation); and personal consultancy fees from Vanda Pharmaceuticals, Inc. Mark E. Howard and Shantha M.W. Rajaratnam report institutional grants paid to Monash University from the CDC Foundation (funding provided by BNY Mellon), and from WHOOP, Inc. Shantha M.W. Rajaratnam reports an institutional grant paid to Monash University from the Cooperative Research Centre for Alertness, Safety and Productivity; consulting fees paid to Monash University from Teva Pharmaceutical Industries, Ltd, Australia and Ukraine, Vanda Pharmaceuticals, Inc., BHP Billiton, and Herbert Smith Freehils; patent PTC/AU2021/050126 for Systems and Methods for Monitoring and Control of Sleep Patterns; and institutional consultancy fees from Circadian Therapeutics. No other potential conflicts of interest were disclosed.
Publisher Copyright:
© 2021. All Rights Reserved.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/8/27
Y1 - 2021/8/27
N2 - What is already known about this topic? Adults with disabilities experience higher levels of mental health conditions and substance use than do adults without disabilities. What is added by this report? During February-March 2021,64.1% of surveyed U.S. adults with disabilities reported adverse mental health symptoms or substance use; past-month substance use was higher than that among adults without disabilities (40.6% versus 24.5%, respectively). Among adults with a diagnosis of mental health or substance use conditions, adults with disabilities more frequently (43% versus 35%) reported pandemic-related difficulty accessing related care and medications. What are the implications for public health practice? During public health emergencies, including the COVID-19 pandemic, enhanced mental health and substance use screening among adults with disabilities and improved access to related health care services are critical.
AB - What is already known about this topic? Adults with disabilities experience higher levels of mental health conditions and substance use than do adults without disabilities. What is added by this report? During February-March 2021,64.1% of surveyed U.S. adults with disabilities reported adverse mental health symptoms or substance use; past-month substance use was higher than that among adults without disabilities (40.6% versus 24.5%, respectively). Among adults with a diagnosis of mental health or substance use conditions, adults with disabilities more frequently (43% versus 35%) reported pandemic-related difficulty accessing related care and medications. What are the implications for public health practice? During public health emergencies, including the COVID-19 pandemic, enhanced mental health and substance use screening among adults with disabilities and improved access to related health care services are critical.
UR - http://www.scopus.com/inward/record.url?scp=85114788300&partnerID=8YFLogxK
U2 - 10.15585/mmwr.mm7034a3
DO - 10.15585/mmwr.mm7034a3
M3 - Article
C2 - 34437518
AN - SCOPUS:85114788300
SN - 1057-5987
VL - 70
SP - 1142
EP - 1149
JO - MMWR Recommendations and Reports
JF - MMWR Recommendations and Reports
IS - 34
ER -
